- It's Time to Renew Your Membership - |
|
There are many benefits to renewing your membership with MSCP/MPA, including:
-
Direct access to experts that can answer law and practice questions
-
Networking opportunities with pharmacy professionals, such as complimentary membership in our local county associations and practice sections
-
Free and discounted CE opportunities such as the MPA Annual Convention and Exposition- the state’s largest pharmacy conference
-
Being part of the collective voice advocating for the future of the profession
-
MPA Career Connect, a free service for you and other pharmacy professionals looking for job opportunities
-
Competitive home, auto and business insurance through MPA’s affiliated PSI Insurance Agency
MPA exists for, and is effective because of, its members. RENEW today to ensure that your benefits are secured and that MPA has the resources to move the mountains ahead for you, for the profession and for patients.
|
|
- Please Take This Brief Survey - |
|
|
What resources could you benefit from having to improve your work place or job satisfaction?
|
|
Workflow management techniques
|
|
|
|
|
CV building and interviewing
|
|
|
|
|
I am not interested in this
|
|
|
|
|
|
|
-
Cover Story: MPA President-elect Hope Broxterman, Pharm.D., shares her vision for building momentum in 2023.
-
From the Foundation: MPF research grants fund a Henry Ford program to provide blood pressure cuffs to patients in need to support self-monitoring.
-
Professional Affairs: The experiences of faculty and students, supported by substantial reporting, illustrate the problem of the lack of representation of darker skin tones in academic journals and textbooks, with concerning consequences for patients and providers.
|
|
|
-
Tech Focus: Get a snapshot of the state of the profession for pharmacy technicians, including survey results from the 2022 Pharmacy Technician Certification Board workforce survey.
-
CE Homestudy: Earn free continuing education credit on the topic of pharmacy's role in tobacco cessation.
Read the latest edition of the Michigan Pharmacists journal online today by clicking the Journal above. Look in your mailbox for the printed version coming soon!
|
|
- Vaccination Partners Sought for People with Disabilities - |
|
The Michigan Developmental Disabilities Institute (MI-DDI) at Wayne State University is looking to expand its Michigan Vaccination Partners (MVP) project to include community pharmacies across Michigan as MVP providers.
MVP's mission is to improve equity and access to vaccinations and other healthcare services. It was created by the Autism Alliance of Michigan (AAoM), Disability Rights Michigan (DRM) and Michigan Developmental Disabilities Institute (MI-DDI) to optimize the impact of the organizations' collective COVID-19 funding from the Michigan Department of Health and Human Services' (MDHHS) COVID-19 Vaccination Supplement. Efforts from this funding aim to ensure greater equity and access to vaccination for people disproportionately impacted by COVID-19, including people with disabilities.
People with disabilities were six times more likely to die from COVID-19, and they also experienced reduced access to routine health care and services. Additionally, people with disabilities faced negative social impacts due to the pandemic, like unemployment and reduced access to medications, food and transportation. Even before the pandemic, people with disabilities were already more likely to report poorer health compared to those without disabilities. These conditions include higher rates of diabetes, chronic obstructive pulmonary disease (COPD), cancer and depression.
|
|
- Pharmacists in Functional Medicine -
By Farzaneh Azizi, Pharm.D., Jamie Vroman, Pharm.D., Chaz Hyatt, Pharm.D., Brittany Myland, Pharm.D., PGY-1 residents, Meijer Pfizer FSU
|
|
What is functional medicine?
Functional medicine is defined as a patient-centered approach to medicine that focuses on addressing the underlying cause of an illness to restore the patient’s health.1,2 This approach in medicine considers health and illness as a continuum with a dynamic interaction between whole human biological systems and environmental factors such as lifestyle and genetic factors influencing gene expression.1,2 Thus, one of the core elements of functional medicine is the collection of thorough patient history to determine potential environmental triggers that will impact the patient’s health.1,2 Rather than focusing on alleviating symptoms or preventing disease progression, functional medicine focuses on multimodal treatment plans, including, but not limited to, diet and nutrition, exercise, stress management, sleep, natural medicine and pharmaceuticals to help restore physiologic imbalances and prevent the emergence of other illnesses.1,3
Despite the initial differing views on functional medicine, in 2018, the American Academy of Family Physicians (AAFP) lifted its moratorium on certain, but not all, continuing medical education related to functional medicine due to the growing body of literature in this field.4,5 These newer studies found that patients with chronic disease states (esp. due to an underlying inflammatory cause) who utilized functional medicine had an improved quality of life (QoL) score compared to the patients who only received standard medical care.6,7 Thus, it is suggested that functional medicine as an adjunct therapy may improve patients’ QoL and pain scores.6,7 However, more studies are needed to determine the effects of functional medicine beyond patients’ QoL improvement as well as to better outline and unify the practice of functional medicine.
What is the pharmacist’s role in functional medicine?
As pharmacists, we are among the most approachable healthcare professions for patients. Pharmacists, especially in community pharmacies and/or clinics, have long utilized medication therapy management (MTM) and/or comprehensive medication reviews (CMRs) to obtain a thorough patient history. Additionally, as pharmacists, we use our knowledge of pharmaceuticals and lifestyle modifications combined with the obtained patient history to answer patients’ questions and customize their medication action plans. These skillsets enable pharmacists to assist other healthcare team members to identify potential medication-induced nutrition deficiencies, medication-related side-effects/diseases, appropriate lifestyle modifications (e.g., diet and nutrition, exercise, smoke cessation, etc.), or opportunities for deprescription when necessary.8,9 Lastly, collaborative practice agreements provide extra opportunities for community pharmacists to work side-by-side with other practitioners in providing effective functional medicine with the intent of holistically restoring health and supporting patients in managing chronic diseases.8,9
Conclusion
In conclusion, pharmacists can play a vital role in advancing and incorporating functional medicine into the current practice. Community pharmacies and collaborative practice agreements provide pharmacists with ample opportunities to utilize functional pharmacy in the daily care of their patients and help holistically address the root cause of many chronic illnesses versus simply alleviating the symptoms.
|
|
References
-
The Institute for Functional Medicine. (2021). Functional Medicine: A Clinical Model to Address Chronic Disease and Promote Well-Being. Functionalmedicine.widen.net. https://functionalmedicine.widen.net/s/pkcvf2wzlj/ifm_functional_medicine_descriptive_paper
-
Cleveland Clinic. (n.d.). What is Functional Medicine? Cleveland Clinic. https://my.clevelandclinic.org/departments/functional-medicine/about
-
The Institute for Functional Medicine. (n.d.). Why Functional Medicine Matters. The Institute for Functional Medicine. https://www.ifm.org/functional-medicine/why-functional-medicine-matters/
-
Bellamy, J. (2017, October 26). AAFP: Functional Medicine lacks supporting evidence; includes “harmful” and “dangerous” treatments | Science-Based Medicine. Sciencebasedmedicine.org. https://sciencebasedmedicine.org/aafp-functional-medicine-lacks-supporting-evidence-includes-harmful-and-dangerous-treatments/
-
Crawford, C. (2018). AAFP Credit System Reconsiders Functional Medicine Topics. www.aafp.org. https://www.aafp.org/news/education-professional-development/20180328functionalmed.html https://www.aafp.org/news/education-professional-development/20180328functionalmed.html
-
Beidelschies, M., Alejandro-Rodriguez, M., Ji, X., Lapin, B., Hanaway, P., & Rothberg, M. B. (2019). Association of the Functional Medicine Model of Care with Patient-Reported Health-Related Quality-of-Life Outcomes. JAMA Network Open, 2(10), e1914017. https://doi.org/10.1001/jamanetworkopen.2019.14017
-
Droz, N., Hanaway, P., Hyman, M., Jin, Y., Beidelschies, M., & Husni, M. E. (2020). The impact of functional medicine on patient-reported outcomes in inflammatory arthritis: A retrospective study. PLoS ONE, 15(10). https://doi.org/10.1371/journal.pone.0240416
-
Hartzler, M. L., Castle, L., Lewis, C., & Zakaria, L. (2020). A functional approach to the chronic disease epidemic. American Journal of Health-System Pharmacy, 77(8), 668–672. https://doi.org/10.1093/ajhp/zxaa032
-
Gregory, T. (2021). Functional Medicine: Finding the Root Cause. www.pioneerrx.com. https://www.pioneerrx.com/blog/functional-medicine-finding-the-root-cause
|
|
- Pharmacists Can Support Individuals Impacted by Intimate Partner Violence -
By Elizabeth Kwast-Pearson, Pharm.D. candidate 2024; David Bright, Pharm.D., MBA, BCACP, FAPhA, FCCP, professor; Susan DeVuyst-Miller, Pharm.D., AE-C, associate professor, Department of Pharmaceutical Sciences, Ferris State University College of Pharmacy
|
|
To provide patients with optimal care, we must first see our patients as people. Looking past the medications and disease states can lead us to discover deeper issues and opportunities to provide care. A commonly overlooked patient health determinant is the environment in which the patient lives. Living with violence negatively impacts patient’s quality of life and increases the risk of long-term medical complications.1 More specifically, Intimate Partner Violence (IPV) can lead to decreased access to care, medication nonadherence and poor health outcomes.1 With 43 million women and 38 million men experiencing IPV in their lifetime, it is important and timely to educate front-line pharmacists on how to identify, treat, document and provide resources to patients experiencing IPV.2
IPV can vary with each instance and situation, but often involves physical, sexual or psychological violence, including stalking, from a current or previous partner.2 The Centers for Disease Control and Prevention (CDC) estimate about one in four women and nearly one in 10 men experience IPV during their lifetime, with only about one in 15 cases being reported.2,3 Community pharmacists are the most accessible healthcare professionals, making them uniquely positioned to be able to help victims suffering from IPV without raising suspicion.4 With the required resources and educational tools, pharmacists could play an integral role in helping victims of IPV. A free online IPV educational tool for healthcare professionals can be found online at endfamilyviolence.uci.edu/projects. Pharmacists are taught to be patient advocates, which includes learning how to care for patients experiencing IPV.
Pharmacists are trained in areas regarding medication counseling, motivational interviewing and taking medication histories from patients. Through this training, pharmacists are taught to use open-ended questions, nonjudgmental language and sensitivity during patient interactions. Using these essential skills and IPV education, pharmacists can screen patients for IPV and provide support by connecting those in need with local resources, documenting the interaction and creating a safety plan with patient autonomy in mind.3
From a legal standpoint, Michigan law section 750.411 states that pharmacists are required to make a report with the local police if a patient comes into the pharmacy or hospital with an injury from a knife, gun, pistol, deadly weapon or other means of violence.5 The report must include the name, residence and whereabouts of the victim, as well as the cause, character and extent of injuries. If known, the identity of the perpetrator must also be reported. Given the legal obligation to report violent injuries, it is essential for pharmacists to disclose this reporting requirement to patients before the assessment of IPV.3 Regardless of the injury, emergency services should be contacted immediately if it is clear that the patient is in danger. This law also highlights the good faith reporting system where pharmacists are protected from civil liability as long as no professional malpractice is suspected. Pharmacists maintain awareness of legal responsibilities for care involving IPV by visiting the Michigan Legislature’s website.
|
|
References:
-
Barnard M, White A, Bouldin A. Preparing Pharmacists to Care for Patients Exposed to Intimate Partner Violence. Pharmacy. 2020;8(2):100. doi:10.3390/pharmacy8020100
-
Violence Prevention. Centers for Disease Control and Prevention. Updated November 2, 2021. Accessed August 29, 2022. https://www.cdc.gov/violenceprevention/intimatepartnerviolence/fastfact.html
-
Chen TT, Gonzalez F, Swift R, Greene E. Pharmacist’s role in recognizing domestic violence. American Journal of Health-System Pharmacy. 2022;79(6):419-420. doi:10.1093/ajhp/zxab427
-
Barnard M, Sinha A, Sparkmon WP, Holmes ER. Reporting interpersonal violence and abuse: What pharmacists need to know. Journal of the American Pharmacists Association. 2020;60(6):e195-e199. doi:10.1016/j.japh.2020.07.014
- Hospitals, pharmacies, physicians; duty to report injuries; violation as misdemeanor; immunity; limitations, Act 328 MCL § 750.411 (1931)
|
|
- Auvelity® (dextromethorphan hydrobromide and bupropion hydrochloride) for Major Depressive Disorder -
By Nikota Redmond, Pharm.D. candidate 2023, Ferris State University College of Pharmacy
|
|
Major depressive disorder (MDD) is a common mental disorder characterized by depressed mood, loss of interest or pleasure in regular activities, decreased energy, feelings of guilt or low self-worth, disturbed sleep or appetite, psychomotor changes and poor concentration. MDD is the most prevalent and disabling form of depression. It consists of immediate symptoms in addition to overall poor quality of life, decreased productivity, increased obesity and sedentary behavior, and increased risk of mortality from suicide and other causes. Some co-morbidities that are associated with MDD are anxiety, post-traumatic stress disorder (PTSD), substance use disorder (SUD) and common illnesses such as diabetes and obesity.
MDD was ranked as the third most common cause of the burden of disease worldwide in 2008 by the World Health Organization (WHO), which has projected that this disease will rank first by 2030. Selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitor (SNRIs) and cognitive therapy are the most commonly prescribed treatments for MDD. Many patients require adjunct therapy such as bupropion, second-generation antipsychotics, T3 (if deficient) or lithium. Even with the wide range of options available, MDD treatment is often ineffective in achieving the common efficacy measure of a reduction of PHQ-9 score of 50 percent.
On Aug. 19, dextromethorphan – bupropion (Auvelity®) was approved for the treatment of MDD in adults 18 years of age or older. Auvelity is the first and only oral N-methyl-D-aspartate (NMDA) receptor antagonist approved for MDD. In clinical trials, Auvelity showed a statistically significant decrease in PHQ-9 score. The most common adverse events were dizziness, nausea, headache, somnolence, dry mouth, sexual dysfunction and hyperhidrosis.
Auvelity is currently available as an oral tablet containing 45 mg of dextromethorphan and 105 mg bupropion. The starting dose is one tablet once daily in the morning. After three days, the dose may be increased to the maximum dosage of one tablet twice daily. A max dose of one tablet daily is recommended for patients with renal impairment (eGFR of 30-59). Other dosage considerations for drug interactions and special patient populations can be obtained in the package insert.
|
|
References:
-
Major depressive disorder - statpearls - NCBI bookshelf. (n.d.). Retrieved September 21, 2022, from https://www.ncbi.nlm.nih.gov/books/NBK559078/
-
APA clinical practice guideline for the treatment of depression across ... (n.d.). Retrieved August 31, 2022, from https://www.apa.org/depression-guideline/guideline.pdf
-
VA/DOD clinical practice guideline for the management of major ... (n.d.). Retrieved August 31, 2022, from https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf
-
U.S. Department of Health and Human Services. (n.d.). Depression. National Institute of Mental Health. Retrieved August 31, 2022, from https://www.nimh.nih.gov/health/topics/depression
-
Auvelity [package insert] Moderate to strong CYP2C19 inhibitors or strong CYP3A4 inhibitors (4 ... (n.d.). Retrieved September 21, 2022, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214998s000lbl.pdf
|
|
|
|
|
|
|
